The efficacy of sorafenib administration prior to TACE against the patients with intermediate HCC refractory to TACE

The efficacy of sorafenib administration prior to TACE against the patients with intermediate HCC refractory to TACE - The efficacy of sorafenib administration prior to TACE

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012636

Enrollment

Registered

2013-12-20

Start date

2013-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC

Interventions

TACE, sorafenib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with HCC refractory to TACE

Exclusion criteria

Exclusion criteria: Patients with contraindication for sorafenib

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
TTP, ORR, OS	—

Countries

Japan

Contacts

Public ContactHirotoshi Ebinuma

Keio University, School of Medicine Division of Gastroenterology & Hepatology

ebinuma@a5.keio.jp03-3353-1211-62384

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026